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ABSTRACT
Diabetic nephropathy (DN) has become a leading cause of end stage renal 
disease (ESRD) in industrialized countries, and most affected patients have 
type 2 diabetes (T2D). Over the last years it has become evident that sterile 
inflammation plays a central role in the pathogenesis of DN. Accumulation of 
macrophages was demonstrated in humans and rodent models of DN, and 
inhibition of inflammatory cell recruitment into the kidney was shown to be 
protective in experimental DN. In addition to immune cells, intrinsic renal 
cells, such as podocytes and mesangial cells, can also secrete pro-
inflammatory cytokines, which may contribute to the inflammatory process 
and aggravate DN.
The aim of the present study was to investigate whether palmitic acid, 
Fetuin-A or their combination elicit an inflammatory response involving toll-
like receptor 4 (TLR4) in podocytes and whether this inflammatory pathway 
affects podocyte survival. Further, I aimed to investigate whether interleukin-
1β (IL-1β) signaling can modulate podocyte death. Finally, I performed a pilot
study in diabetic mice to investigate whether inhibition of IL-1β with a 
murinized anti-IL-1β antibody may attenuate albuminuria and/or surrogate 
markers of DN.
The present study uncovered that Fetuin-A or LPS exacerbate palmitic acid 
induced podocyte death, which is associated with a strong inflammatory 
response as indicated by the induction of monocyte chemoattractant protein-
1 (MCP-1) and keratinocyte chemoattractant (KC). Moreover, blockage of 
TLR4 dramatically decreased MCP-1 and KC secretion and attenuated 
podocyte death induced by palmitic acid alone and/or Fetuin-A in 
combination with palmitic acid. In addition, inhibition of IL-1 signaling by 
anakinra, a recombinant human IL-1Ra, or a murinized anti-IL-1β antibody 
attenuated the inflammatory response elicited by Fetuin-A and palmitic acid 
and - similar to TLR4-inhibition - attenuated podocyte death.
In vivo, therapy of diabetic DBA/2J mice with an anti-IL-1β antibody 
prevented an increase in serum Fetuin-A concentrations and considerably 
decreased tumor necrosis factor alpha (TNF) secretion in the urine, which is 
thought to correlate reciprocally with DN progression. In the short term, 
however, therapy with the anti-IL-1β antibody was not able to protect from 
albuminuria.
In summary, the results suggest that Fetuin-A leads to an inflammatory 
response in podocytes which exacerbates palmitic acid induced podocyte 
death. The data suggest also that TLR4 signaling plays a role as a modulator 
in the initiation and perturbation of the inflammatory process and leads to an
exacerbation of palmitic acid induced podocyte death. In addition, this study 
implies a critical role for IL-1β signaling in palmitic acid induced podocyte 
death. In vivo, therapy of diabetic mice with an anti-IL-1β antibody favorably 
affected Fetuin-A levels in serum and urinary TNFα-levels, but in the short 
term a beneficial effect on albuminuria was absent, which gives the rational 
for prolonged studies to further test this new therapeutic approach. 
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1. INTRODUCTION
1.1. Diabetic Nephropathy
1.1.1. Epidemiology
Diabetic nephropathy is the most common cause end-stage renal disease 
(ESRD), it may affect one third of patients with diabetes mellitus (Molitch 
et al., 2004; "Type 2 diabetes in children and adolescents. American 
Diabetes Association," 2000). In many parts of the word, its incidence 
increased alarmingly over the last decades, which is related to the 
increase in obesity and type 2 diabetes (T2D). A further substantial 
increase is expected by 2050 (Reutens & Atkins, 2011). In some parts of 
the word, e.g. in the U.S., no further increase of incident DN was observed 
although its prevalence is still increasing (Burrows, Li, & Geiss, 2010). This 
finding suggests that strategies including early diagnosis, early initiation of
therapy, and the use of more effective renoprotective medications are 
efficacious.
More recently, T2D - once thought to be a metabolic disorder of adulthood 
- has become increasingly more frequent in obese adolescents (Pinhas-
Hamiel & Zeitler, 2005) and raised from less than 3% of all cases of new-
onset diabetes in the 80s and 90s to 45% in adolescents by the end of the 
last century ("Type 2 diabetes in children and adolescents. American 
Diabetes Association," 2000).
1.1.2. Overview of factors contributing to the progression of 
diabetic nephropathy
There are several factors known to be imbalanced in the diabetic condition
and which are thought contribute to the pathogenesis of DN including 
hyperglycemia (Susztak & Bottinger, 2006), impaired insulin signaling 
(Madhusudhan et al., 2015), advanced glycation end products (Chuang, 
Yu, Fang, Uribarri, & He, 2007) activation of cytokines (Lim & Tesch, 2012), 
and dyslipidemia (Sieber & Jehle, 2014). There is no single driving force 
that leads to DN, but a combination of factors that drive progression of DN.
In diabetic patients, tissues including the liver, adipose tissue, and skeletal
muscle are affected by impaired insulin signal (Wilcox, 2005). Insulin 
resistance and relative or absolute lack of insulin (insulinopenia) lead to 
hyperglycemia (Rosival, 2007) and release of FFAs into the circulation 
which may exacerbate insulin resistance (Sieber & Jehle, 2014). FFAs can 
accumulate in the glomeruli (Bobulescu, 2010) and may cause cellular 
damage in a process named lipotoxicity (Schaffer, 2003). Chronic low 
grade inflammation critically contributes to the pathogenesis of T2D 
(Donath & Shoelson, 2011) and accumulating evidence suggests that 
inflammation plays also a significant role in the pathogenesis of DN 
(Navarro & Mora, 2005).
1.1.3. Podocytes in the pathogenesis of DN
The kidney glomerular filter is a charged-selective barrier that allows blood
filtration without loss of large proteins into the urine. The filtration unit in 
the kidney has three layers: fenestrated endothelial cells, the glomerular 
basement membrane (GBM), and podocytes. Defects in any of the three 
layers in the glomeruli can lead to proteinuria. The prominent role of 
podocytes for the function of the glomerular filter is illustrated by the 
identification of single human gene defects important for podocyte 
function, which lead to heavy proteinuria and the so called nephrotic 
syndrome (proteinuria over 3g per day, oedema, hypoalbuminemia) 
(Greka & Mundel, 2012).
Moreover, podocytes critically determine the biophysical characteristics of 
the GBM and are important to counteract the hydrostatic pressure from 
the glomerular capillaries (Endlich & Endlich, 2006).
Figure 1: Structure of the glomerular filtration barrier. A) Schematic picture of the 
glomerular filtration barrier consisting of fenestrated endothelium cells, the glomerular basement 
membrane (GBM), and podocytes with their interdigitating foot process (Image from (Patrakka & 
Tryggvason, 2010). B) Image taken using a scanning electron microscope of a podocyte wrapped 
around a glomerular capillary (Image from (Smoyer & Mundel, 1998).
In response to injury, podocytes may undergo a number of different fates 
that include proliferation, de-differentiation, or apoptosis. Podocytes are 
highly differentiated epithelial cells with low capability to undergo cell 
division (Kriz, 2003; Reidy & Kaskel, 2007).
Damage and loss of podocytes critically contributes to DN (Wolf, Chen, & 
Ziyadeh, 2005). It is well reported in T1D and T2D patients that they have 
a reduced number and density of podocytes (Dalla Vestra et al., 2003; 
Pagtalunan et al., 1997; Steffes, Schmidt, McCrery, & Basgen, 2001; White 
& Bilous, 2000, 2004). Importantly, podocyte loss directly correlates with 
proteinuria(White & Bilous, 2004). Even more, a study performed in Pima 
Indians with T2D suggests that a reduced number of podocytes per 
glomerulus predicts progressive kidney disease (Meyer, Bennett, & Nelson,
1999).
1.1.4. Factors contributing to apoptosis of podocytes in DN
It has become clear that hyperglycemia alone is neither the only 
contributing factor nor sufficient to cause diabetic kidney disease and 
podocyte death. An increasing number of hemodynamic, metabolic, 
BA B
inflammatory, structural, and genetic factors have been identified in the 
disease process (Dronavalli, Duka, & Bakris, 2008).
In vitro, high glucose concentrations have been reported to induce 
apoptosis of podocytes, and increased ROS (reactive oxygen species) 
levels have been shown to be important mediators of glucotoxicity (Eid et 
al., 2009; Kanwar et al., 1996; Susztak & Bottinger, 2006). ROS do not 
result from hyperglycemia only, but are also stimulated by angiotensin II 
(ANG II). Transforming growth factor (TGF-) is another important factor 
leading to podocyte death (Schiffer, Daxenberger, Meyer, & Meyer, 2001; 
T. Wada, Pippin, Terada, & Shankland, 2005). In the diabetic milieu, TGF- 
is induced by many factors including ROS, ANG II, and advanced glycation 
end products (Ziyadeh, 2004). Administration of neutralizing anti-TGF-β 
antibodies in db/db mice was found to prevent mesangial matrix 
expansion and to protect from a decline in kidney function (Ziyadeh et al., 
2000).
In the following I will introduce in more detail the role dysregulated lipid 
metabolism as well as inflammation in the pathogenesis of podocyte 
damage and DN.
1.2. Lipotoxicity in the pathogenesis of DN
Elevated FFAs in the circulation lead to lipid accumulation in non-adipose 
tissues including the pancreas, heart, liver, and the kidneys. Excessive 
lipid droplets can be found in different renal cell types including podocytes 
(de Vries et al., 2014; Herman-Edelstein, Scherzer, Tobar, Levi, & Gafter, 
2014). Lipid deposition causes cell dysfunction and death. This process is 
term lipotoxicity (Brookheart, Michel, & Schaffer, 2009).
Disturbed fatty acid metabolism and elevated FFAs are critical 
determinants of lipotoxicity (Brookheart et al., 2009). Up to 80% of the 
plasma FFAs consist of the saturated palmitic acid (C16:0) and stearic acid 
(C18:0) as well as the monounsaturated oleic acid (C18:1) (Hagenfeldt, 
Wahren, Pernow, & Räf, 1972), though quantification of FFAs in circulation 
is controversial due to their tendency to aggregate. Adipocytes of obese 
individuals can become defective in FFA uptake, which adds to elevated 
FFA-levels and favors ectopic fat deposition (McQuaid et al., 2011). This is 
of interest as plasma FFA composition partially reflects dietary fatty acids 
(Fielding et al., 1996) and saturated FFAs (SFAs) and monounsaturated 
FFAs (MUFAs) have distinct effects on cell metabolism and function. The 
toxicity of FFAs has been attributed mainly to SFAs whereas MUFAs exert 
beneficial and cytoprotective effects (Brookheart et al., 2009; Nolan & 
Larter, 2009).
Dysregulared fatty acid metabolism is thought to play an important role in 
the development of DN and in kidney diseases related to metabolically 
unhealthy obesity (Sieber & Jehle, 2014). Diabetic patients present an 
altered serum lipid profile characterized by elevated triglyceride (TG) 
concentrations beginning in the earliest stages of microalbuminuria (Murea
et al., 2010). Dyslipidemia may affect the kidney directly by causing 
deleterious renal lipid accumulation and indirectly through systemic 
inflammation, oxidative stress, vascular injury, and changes in hormones 
and other signaling molecules with renal action (Bobulescu, 2010).
1.2.1. Effects of FFAs and of their metabolism on podocyte 
survival
Our lab has shown that palmitic acid increases podocyte death in a dose- 
and time-dependent fashion. Palmitic acid induces podocyte ER 
(endoplasmatic reticulum) stress leading to an unfolded protein response 
as reflected by the induction of the ER chaperone immunoglobulin heavy 
chain binding protein (BiP), and proapoptotic C/EBP homologous protein 
(CHOP) transcription factor, and gene silencing of CHOP protects at least in
part from palmitic acid induced podocyte death (Sieber et al., 2010).
Similar to other cell types including pancreatic β-cells (Maedler, 
Oberholzer, Bucher, Spinas, & Donath, 2003) and human mesangial cells 
(Mishra & Simonson, 2005) MUFAs protect podocytes from palmitic acid 
induced cell death (Sieber et al., 2010). Tracing studies with tritium-
labeled palmitic acid demonstrated that oleic acid leads to preferential 
incorporation of palmitic acid derived metabolites into TGs (Sieber et al., 
2013). In other words, oleic acid may reduce palmitic acid-induced 
podocyte death by shifting palmitic acid and its toxic metabolites to “safe”
TG pools. Furthermore, oleic acid stimulates -oxidation of palmitic acid 
and may be beneficial simply by reducing the levels of palmitic acid and 
its toxic metabolites (Kampe, Sieber, Orellana, Mundel, & Jehle, 2014).
1.3. Inflammation in the pathogenesis of DN
Chronic low grade inflammation is thought to be one of the most important
underlying mechanisms in the pathogenesis of T2D (Donath & Shoelson, 
2011). Similarly, accumulating evidence suggests that inflammation plays 
a significant role in the pathogenesis of DN (Navarro & Mora, 2005). 
Interestingly, it is suggested that there is a reciprocal relationship between
the metabolic syndrome and chronic inflammation (Hotamisligil, 2006).
Accumulation of macrophages was demonstrated in humans and rodent 
models of DN (F. Chow, Ozols, Nikolic-Paterson, Atkins, & Tesch, 2004; 
Nguyen et al., 2006) and inhibition of inflammatory cell recruitment into 
the kidney was shown to be protective in experimental DN (Awad et al., 
2011; F. Y. Chow, Nikolic-Paterson, Ozols, Atkins, & Tesch, 2005). In addition
to immune cells, intrinsic renal cells such as podocytes and mesangial 
cells can also secrete pro-inflammatory cytokines, which may contribute to
the inflammatory process and aggravate DN (Sayyed et al., 2009; Tesch et 
al., 1997)
1.3.1. Toll-like receptors and DN
Toll-like receptors (TLRs) are considered to play a key role in the initiation 
and perturbation of the inflammatory process underlying diabetes and its 
complications (Lin & Tang, 2014). TLRs recognize pathogen-associated 
molecular patterns such as lipopolysaccharide (LPS), and viral or bacterial 
nucleic acids (Akira, Takeda, & Kaisho, 2001). Activation of TLRs leads to 
recruitment of adaptor proteins, which subsequently trigger downstream 
signaling cascades resulting in activation of nuclear factor-κB (NF-κB) 
(Akira et al., 2001). The transcription factor NF-κB induces a wide range of 
cytokines including interleukin-1β (IL-1β) (Hiscott et al., 1993) and 
monocyte-chemoattractant protein-1 (MCP-1) (Ueda et al., 1994). 
Importantly, it has been shown that TLRs are not activated by pathogen-
associated molecular patterns only but also by endogenous danger signals
released during tissue injury or metabolic stress (Akira et al., 2001).
T2D is characterized by hyperglycemia and dyslipidemia with increased 
levels of free fatty acids (FFAs) (Randle, Garland, Hales, & Newsholme, 
1963). Over the last years growing data indicate that FFAs can induce the 
production of pro-inflammatory cytokines through activation of TLR4 
and/or TLR2 (Boni-Schnetzler et al., 2009). However, how FFAs activate 
TLRs is a subject of debate and current evidence suggests that FFAs do not
directly bind to TLR4 (Erridge & Samani, 2009). Recently, a model was 
suggested with Fetuin-A (FetA) as an endogenous ligand and potential 
molecular linker for FFAs to TLR4 (Pal et al., 2012).
1.3.2. Fetuin-A
Fetuin-A (FetA) is a liver-derived, abundant plasma protein which is 
involved in multiple biological functions. The function of FetA is best 
studied as a carrier protein for otherwise insoluble mineral and as an 
inhibitor of ectopic calcium deposition (Jahnen-Dechent, Heiss, Schafer, & 
Ketteler, 2011). In addition and already dating back to the 90’s, FetA is 
known as a major carrier protein of FFAs in the circulation (Cayatte, 
Kumbla, & Subbiah, 1990). Urinary FetA is also a new candidate marker to 
predict progression of DN (Inoue et al., 2013). The first study which 
suggests that FetA might be the missing linker of FFAs to TLR4 was 
published in Nature Medicine by Bhattacharya and co-authors (Pal et al., 
2012).
Figure 2: Model for Fetuin-A linking FFAs to TLR4 signaling. Fetuin-A is proposed to be the 
link between FFAs and the TLR4 pathway. TLR4 signaling leads to the activation of NF-κB, which 
upregulates the transcription of inflammatory genes including pro-Il-1β. Pro-Il-1β is processed by 
the inflammasome associated caspase-1. In turn, Il-1β sustains autocrine (and paracrine) activation 
of local cells including podocytes which leads to a chronic inflammatory response in the kidney and 
promotes chronic kidney disease.

1.3.3. Interleukin-1β
Interleukin-1β is a master regulator of inflammation in various tissues 
(Dinarello, 2009). Intrinsic renal cells including podocytes are major 
sources of IL-1β in experimental models of glomerulonephritis (Niemir et 
al., 1997).
The potential role of IL-1β in the pathogenesis of DN dates back to 1996 
when it was reported that an allele of the IL-1 receptor antagonist (IL-1Ra),
which finally leads to increased IL-1 signaling, is associated with DN 
(Blakemore et al., 1996). IL-1 β induces also other chemokines, which in 
turn attracts macrophages (Ehses et al., 2009). The vicious cycle is further
amplified as IL-1 β can induce lipoprotein lipase which may further 
increase local and systemic concentrations of free fatty acids (Dinarello, 
2011). More recently, it was found that IL-1β is elevated in plasma and in 
renal cortex extracts at the onset of DN, and anakinra, a recombinant 
human IL-1Ra, can prevent or even reverse DN in different mouse models 
(Shahzad et al., 2015).
1.4. Aim of the study
Increasing evidence suggests that in the pathogenesis of DN podocyte 
injury and loss are critical events and determine disease progression and 
precede proteinuria. Several factors of the diabetic milieu are known to 
impair function and survival of podocytes. Although lipid accumulation is a 
well know feature of DN, only recently the potentially important role of 
FFAs and FFA metabolism in this process were acknowledged. 
Over the last years our laboratory systematically analyzed the effects of 
FFAs and FFA metabolism on podocyte survival. The objective of the 
present study was to investigate whether FetA or TLR4 activation by LPS 
exacerbates palmitic acid induced podocytes death and whether this may 
involve inflammatory pathways with a special focus on IL-1β. In a 
preliminary study in vivo, I investigated the effect of an anti-IL-1β antibody
on insulinopenic DBA/2J mice on a high fat diet.
2. MATERIAL AND METHODS
2.1. Cell culture & Reagents
Podocytes were cultured following the protocol described by Mundel et al. 
(Shankland, Pippin, Reiser, & Mundel, 2007). Conditionally immortalized 
mouse podocytes obtained from Peter Mundel carry a thermosensitive 
variant of the SV 40 T antigen as a transgene (Shankland et al., 2007). 
Podocytes were cultured in RPMI-1640 (#21875, Invitrogen), enriched with
10% heat-inactivated FBS (#10270, Invitrogen) and 100 U/ml 
penicillin/streptomycin (#15140, Invitrogen). Podocytes proliferated under 
growth-permissive conditions at 33°C with IFN-gamma (IFNγ) (#CTK-358-
2PS, MoBiTec GmbH, Germany), and differentiate for 11 days without IFN-γ
at 37°C (Sieber et al., 2013). Podocytes having a passage number from 4 
to 14 were employed for experiments. Cell culture plates and flasks used 
in all assays were coated with type I collagen (BD Biosciences). For 
freezing cells complete culture medium was employed supplemented with 
8% (v/v) dimethylsulfoxide (D2438, Sigma).
Table 1: Agonist, inhibitors and used compounds
Substanc
e
Catalog 
number
Supplier Action Working 
concentration
LPS L2630 Sigma TLR4 activator 10 pg to 1 μg/ml
Fetuin-A, 
Bovine
Non 
commercialize
d product
Provided by 
Prof. Jahnen-
Dechent, 
Aachen 
University
Carrier protein, 
TLR4 activator, 
Insulin inhibitor
200 μg/ml, < 0.06 
EU/ml
tested with Endosafe 
ultrasensitive PTS, 
Charles River.
Fetuin-A, 
murine
Non 
commercialize
d product
Donated by 
Prof. 
Bhattacharya. 
Visva-Bharati 
University
Carrier protein, 
TLR4 activator, 
Insulin inhibitor
200 – 350 μg/ml, 
<0.005 EU/ml tested 
with EndoTrap® HD, 
Hyglos GmbH.
Anakinra Kineret® SOBI IL-1 receptor 
antagonist
1 μg/ml
TAK-242 tlrl-cli95 Invivogen TLR4 signaling 
inhibitor
0.1 μg/ml
Anti IL-1 
β Ab
Non 
commercialize
d product
Novartis IL-1β signaling 
inhibitor
3.3 μg/ml
IL-1 β I5271 Sigma Inflammatory 
citokine
5 ng/ml
2.2. Free fatty acids preparation
Palmitic acid 10 mM (P9767, Sigma) was dissolved overnight in 11% 
essential fatty-acid free low endotoxins BSA (A8806, Sigma) in RPMI [-]D-
glucose(11879-020, LuBioscience), shaken at 37°C under N2-atmosphere 
for 20 min, sonicated for 10 min, sterile filtered, and stored at −20°C. The 
molar ratio of fatty acid to BSA was 6:1. Before use, the complexes were 
heated at 37°C for 15 min followed by dilution in media. BSA used for 
control experiments was prepared and handled exactly the same as BSA 
complex to FFAs (Boni-Schnetzler et al., 2009). The effective free fatty acid
concentrations were measured with a commercially available kit (Wako).
2.3. Removal and measurement of endotoxins
Fatty acid preparations, bovine and murine FetA (Pal et al., 2012), were 
cleaned of endotoxins with EndoTrap® HD (800063, Hyglos GmbH). 
Endotrap is supplied in prepacked columns that contain an affinity matrix 
for the efficient removal of endotoxins from aqueous solutions. Endotrap 
columns can be used more than 10 times. Our preparations were passed 
through the columns 4 times. Each round of application should yield a two 
log reduction of endotoxins. According to manufacturer, loss of proteins 
resulting from binding to endotrap is extremely low, less than 5%. 
Concentration of solutions after and before cleaning the samples was 
determined by DC Protein Assay (Bio-Rad).
The endotoxin concentration was subsequently measured with ToxinSensor
Chromogenic LAL Endotoxin Assay Kit (L00350C, GenScript) following 
manufacturer instructions. Limulus Amebocyte Lysate (LAL) is an extract of
circulating blood cells of the American Horseshoe crab. Endotoxins cause 
amebocytes clotting and trigger the turbidity. This enzymatic reaction 
leads to a colorimetric reaction that allows the quantification of endotoxin. 
All reactions were performed strictly in a constant temperature of 37°C in 
the heating block. Tips and plasticware used were endotoxin-free. The 
level of endotoxins was confirmed to be <0.005 EU/ml.
2.4. Toll-like receptor activation assay
TLR4 activation assay was done by using HEK-Blue hTLR4 reporter cells 
(Invivogen). Cells were generated by co-transfecting HEK293 cells with 
hTLR4 gene, MD-2/CD14 co-receptor genes and a secreted embryonic 
alkaline phosphatase (SEAP) reporter gene. SEAP is expressed under the 
control of the IL-12 p40 minimal promoter fused to five NF-κB and AP-1 
(Activator protein-1) binding sites.
Cells were cultured in 75 cm2 flasks with DMEM (#41965, Invitrogen) 
media including 4.5 g/l glucose, 2-4 mM L-glutamine, 10% FBS, 
penicillin/streptomycin, and Normocin according to manufacturer 
instructions. Experiments were done in 96-well plates with palmitic acid in 
the presence of FetA, ranging from 0 μg/ml to 150 μg/ml or LPS, ranging 
from 10 pg/ml to 104pg/ml for 6h. Secreted SEAP turned the cell culture 
media in purple/blue color, which was quantified with Synergy H1 hybrid 
reader (BioTek).
2.5. Apoptosis assay
Experiments were performed in six-well plates, cultured in RPMI-1640, with
0.2% heat-inactivated FBS. Supernatants were collected, cells were 
trypsinized and harvested by rinsing with complete media (DMEM/10% 
FBS/penicillin/streptomycin) and kept on ice. Cells were centrifuged at 
1400 rpm at 4°C for 5 minutes, and pellet was washed twice with 500 μl 
cold PBS. Cells were resuspended in 100 μl annexin-binding buffer (10 mM 
Hepes/140 mM NaCl/2.5 mM CaCl2, pH 7.4) and incubated for 15 min in 
dark at room temperature with 1:25 Alexa Fluor 647 annexin V conjugate 
(A23204, life technologies). The sample final volume was 500 μl by adding 
annexin-binding buffer. Before analyzing the samples 0.5 μg propidium 
iodide (P3566, Invitrogen) was added to identify necrotic cells (Sieber et 
al., 2013). 20,000 events were acquired by Accuri C6 flow cytometer (BD 
Bioscience, Mountain View, CA). Data from flow cytometry was analyzed 
by the software program FLOWJO (Tree Star, Ashland, OR). Annexin V-
positive/PI-negative podocytes were considered apoptotic, while double 
positive cells were considered late apoptotic/necrotic cells.
2.6. Measurement of cytokines and chemokines
Differentiated podocytes cultured in 75 cm2 flasks were re-seeded in 96-
well plates for 24h, at 6000 cells/well. Before the experiment, cells were 
synchronized in serum starvation medium (RPMI-1640, with 0.2% heat-
inactivated FBS and 5 mM/l glucose) for 16 hrs and for the experiments 
same medium was maintained. After the experiment, supernatants were 
centrifuged at 11000 rpm for 3 minutes and were diluted 1:20 for the 
detection of MCP1. For the detection of KC no dilution was done. MCP1 and
KC expression was quantified using Duoset ELISA kit according to 
manufacturer instructions (DY479 for MCP-1; DY453 for KC, R&D Systems 
purchased from Zug, Switzerland).
2.7. Animal experimentation
For the animal experiments, 8-week-old DBA/2J (DBA) male mice were 
purchased from Charles River (Sulzfeld, Germany) and for experiments 
with C57BL6/N (B6), 4 week old male mice were purchased from Janvier 
labs, France. Mice were maintained in 12h-light/12h-dark cycle and 
provided food and water ad libitum. For DBA experiments, mice were 
randomly divided into four groups: group 1: control (Chow diet) + saline 
(n=6), group 2: control (Chow diet) + anti IL-1β Ab (n=6); group 3: STZ 
(HFD) + saline (n=6); group 4: STZ (HFD)+ anti IL-1β Ab (n=6).
For experiments with B6 mice, animals were divided into four groups: 
group1: control +saline (n=6), group 2: control + anti IL-1β Ab (n=6), 
group 3: STZ + saline (n=6), group 4: STZ+ anti IL-1β Ab (n=6). All 
experiments with mice were performed following the Swiss veterinary law 
and institutional guidelines.
2.7.1. Induction of diabetes and anti IL-1β treatment
To induce diabetes, DBA mice were injected with 40 mg/kg of 
streptozotocin (STZ) (Sigma-Aldrich, St. Louis, MO) intraperitoneally for 
five days, freshly prepared in 50 mmol/l sodium citrate buffer at pH 4.5. 
Control mice were injected with sodium citrate buffer alone. One week 
after the injections group 3 and 4 mice were place on a high-fat diet (HFD) 
after confirming hyperglycemia (glucose >= 14 mmol/l). HFD with 60% of 
fat (lard) source was purchased from ssniff GmbH, Germany (Catalog no. 
E15742-34). Anti IL-1β antibody (Ab) was kindly provided by Novartis, 
Basel, under a material transfer agreement (2015). Antibody was injected 
intraperitoneally once a week at 10 µg/g of mouse for the first two weeks 
and then at 5 µg/g of mouse until the end of the experiment (4 weeks). 
Saline injections were given in control mice (groups without antibody 
administration).
For inducing diabetes in B6 mice, 5-week-old mice were placed on HFD 
(D12331, Research Diets, New Brunswick, NJ) containing 58, 26 and 16% 
calories from fat, carbohydrate, and protein. In the 9th week, mice were 
injected with a single dose of STZ (i.p., 130 mg/kg of mouse) along anti IL-
1β antibody at 10 µg/g of mouse for first two weeks and then at 5µg/g of 
mouse until the end of the experiment (4 weeks).
2.7.2. Measurement of blood glucose, serum Fetuin-A, urinary
TNF-, and urinary albumin levels
For measuring the fasting blood glucose, mice were fasted for 6 hrs in the 
morning and measurements were done using a Glucometer (Freestyle; 
Abbott Diabetes Care Inc., Alameda, CA) by taking a drop of blood from tail
vein. Serum FetA and urinary TNF-α were measured using Duoset Elisa kit 
(R&D Systems) and mesoscale kit (Mesoscale Discovery, Rockville, MD), 
respectively, following the manufacturer’s instructions. Urinary albumin 
levels were determined by employing a kit from Exocell (Philadelphia, USA)
following the manufacturer’s instructions.
2.8. Statistical analysis
All experiments were performed at least three times, and a representative 
experiment is shown. Data are expressed as means ± SD unless otherwise
indicated. One way ANOVA was performed and for calculating significance 
of differences, Bonferroni post hoc test was employed. The prism 6 
program was used for the analysis and differences were considered 
significant when P value was < 0.05.
3. RESULTS
3.1. Inflammatory response to FFAs and/or Fetuin-A in 
podocytes
3.1.1. Fetuin-A but not palmitic acid or oleic acid stimulate 
MCP-1 or KC secretion in podocyte
To investigate whether palmitic acid leads to an inflammatory response in 
podocytes, we measured MCP-1 and KC in the supernatant of podocytes 
after incubation with 75 μM palmitic acid for 12 hours. As shown in figures 
3 and 4, palmitic acid did not stimulate the secretion of these cytokines 
compared to the control media with BSA not complexed to palmitic acid. 
As it has been suggested that FetA may be necessary for the inflammatory
response elicited by palmitic acid (Pal et al., 2012), podocytes were 
incubated with FetA or FetA combined with palmitic acid (Figures 3 and 4). 
In contrast to palmitic acid, FetA significantly stimulated MCP-1 and KC 
secretion by 368 ± 57% (p<0.001) and by 1729± 135% (p<0.001), 
respectively, and the combination of FetA and palmitic acid led to a further
increase of MCP-1 and KC by 229±28% (p<0.001) and by 194 ± 3% 
(p<0.001) compared to FetA alone.
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Figure 3: Murine Fetuin-A but not palmitic acid stimulates MCP-1 secretion in podocytes.
MCP-1 release was quantified in podocytes treated with 75μM palmitic acid (or BSA control) in the 
presence or absence of 150-350 μg/ml bovine FetA. Bar graph represents mean ± SD of MCP-1 
levels (in pg/mL) in the culture media at 12 hrs of treatment. (n = 6, ***p < 0.001).
0
200
400
600
800
1000
1200
Medium BSA Palm FetA 350µg FetA 350µg
Palm
FetA 150µg
Palm
*** 
*** 
*** 
KC
pg
/m
l
Figure 4: Murine Fetuin-A but not palmitic acid stimulates KC secretion in podocytes. KC 
release was quantified in podocytes treated with 75μM palmitic acid (or BSA control) in the 
presence or absence of 150-350 μg/ml bovine FetA. Bar graph represents mean ± SD of KC levels 
(in pg/mL) in the culture media at 12 hrs of treatment. (n = 6, ***p < 0.001).
As shown it Figure 5, similar results were obtain for oleic acid which was 
not able to stimulate MCP-1 secretion significantly, but FetA combined with
oleic acid significantly increased MCP-1 by 173 ± 10% (p<0.001) 
compared to FetA alone.
Figure 5: FetA alone or in combination with free fatty acids induces MCP-1, and the TLR4
blocker TAK-242 prevents chemokine induction. MCP-1 secretion was analyzed in podocytes 
treated with 75 μg/ml palmitic acid, 75 μg/ml oleic acid alone or in combination with 200 μg/ml FetA
in the presence or absence of TAK-242. Bar graph represents mean ± SD MCP-1 levels (in pg/mL) in 
the culture media at 16 hrs of treatment. TAK-242 was applied 1h prior to treatment (n = 4, ***p < 
0.001). Insert: TAK-242 prevents LPS induced MCP-1 release. Podocytes were pretreated with TAK-
242 (or vehicle) and subsequently incubated with 5 ng/ml LPS. Bar graph represents mean ± SD 
MCP-1 levels (in pg/mL) in the culture media at 16 hrs of treatment (n = 4, **p < 0.01).
As the proinflammatory response of FetA is reported to involve TLR4, we 
inhibited TLR4 signaling with TAK-242 (resatorvid), a specific small-
molecule inhibitor of TLR4 signaling. TAK-242 completely prevented the 
increased MCP-1 secretion by the prototypic TLR ligand LPS (Figure 5, 
insert) as well as FetA in combination with palmitic or oleic acid (Figure 5).
3.1.2. Fetuin-A and LPS activates TLR4 in a dose dependent 
manner
To further investigate the potential role of FetA in stimulating the TLR-4 
signaling pathway, I used a commercially available TLR4 reporter cell line. 
As shown in figure 6, increasing concentrations of FetA from 50 to 150 
μg/ml dose dependently stimulated TLR4 similar to a logarithmic increase 
of lipopolysaccharide (LPS) concentrations.
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Figure 6: LPS and murine Fetuin-A activate TLR4 dose-dependently. TLR4 activity was 
measured in HEK-Blue™ hTLR4 cells treated with LPS (10 pg, 100 pg/ml, 103 pg/ml, 104 pg/ml) or 
FetA in the absence or presence of palmitic acid (0 μg/ml, 50 μg/ml, 100 μg/ml, 150 μg/ml) for 18h. 
Bar graph represents mean percentages ± SD of O.D. at 655nm (n = 3).
3.1.3. Fetuin-A aggravates palmitic acid induced podocyte 
death, and TLR4 inhibition attenuates palmitic acid 
induced podocyte death
Previously, we reported that palmitic acid dose- and time-dependently 
induces podocyte death (Sieber et al., 2010). To investigate whether FetA 
modulates cell death induced by palmitic acid, podocytes were treated 
with FetA alone or in combination with 200 μM palmitic acid for 48 hours. 
As shown in Figure 7, FetA had no effect on podocyte viability, but 
exacerbated palmitic acid induced podocyte death. Specifically, FetA 
further increased apoptotic podocytes (Annexin V single positive cells) by 
20.6 ± 0.6% (p < 0.05). In this experiment, no further increase in necrotic 
(Annexin V, PI double positive cells) podocytes could be measured due to 
the disintegration of late necrotic podocytes, a well-known phenomenon 
reported previously by us (Sieber et al., 2010). Similarly, we observed that 
LPS had no effect on podocyte death, but increased palmitic acid induced 
apoptosis 28.5 ± 7.2% (p < 0.001) (Figure 8). TAK-242 could prevent the 
FetA induced increase in apoptotic podocytes (Figure 7) as well as the 
increase induced by LPS (Figure 8).
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Figure 7: Bovine Fetuin-A aggravates palmitic acid-induced podocyte death, which can 
be attenuated by TLR4 inhibition. Podocytes were preincubated with 1 ng/ml TAK-242 for 1 h 
and treated with 200 μM palmitic acid in the presence or absence of FetA (200 µg/ml) for 48 hrs. 
Bar graph represents the mean percentages ± SD of apoptotic and necrotic podocytes (n = 3, **p <
0.01, ***p < 0.001).
Of note, compared to podocytes treated with palmitic acid alone, the 
presence of TAK-242 decreased palmitic acid induced apoptosis by 79.3 ± 
0.7% (p < 0.001) and necrosis by 65.3 ± 5% (p < 0.001) (Figure 7). This 
effect was unexpected and may indicate modulation of podocyte death by 
a constitutive activation of TLR4, which can be blocked by TAK-242.
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Figure 8: LPS aggravates palmitic acid-induced podocyte death, which can be 
attenuated by TLR4 inhibition. 
Podocytes were preincubated with 1 ng/ml TAK-242 for 1 h and treated with 200 μM palmitic acid in 
the presence or absence of or LPS (5 ng/ml) for 48 hrs. Bar graph represents the mean percentages 
± SD of apoptotic and necrotic podocytes (n = 3, **p < 0.01, ***p < 0.001).
3.1.4. IL-Ra and anti-1Lβ antibody attenuate FetA induced 
MCP-1 secretion in podocytes
The proinflammatory cytokine IL-1β is not only involved in the 
pathogenesis of experimental models of glomerulonephritis but also 
contributes to the development of diabetic nephropathy. To investigate 
whether IL-1β is involved in MCP-1 secretion induced by FetA and palmitic 
acid, I used a recombinant human IL-1Ra antagonist (anakinra) and a 
murinized neutralizing anti-IL-1β antibody. I treated podocytes with 200 
μg/ml FetA alone or in combination with 75 μM palmitic acid for 16 hrs. 
FetA alone increased MCP-1 release by 227%  31 (p<0.001), and the 
combination of FetA and palmitic induced a further significant increase.
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Figure 9: TLR4 inhibition and IL-1 neutralization prevent the MCP-1 release mediated by 
the combination of Fetuin-A and palmitic acid. Podocytes were preincubated with 1 ng/ml TAK-
242, 1 μM anakinra or 3.3 μg/ml IL-1β anti-IL-1β antibody and subsequently treated with 75 μM 
palmitic acid alone or in combination with 200 μg/ml FetA. Bar graph represents mean ± SD of MCP-
1 levels (in pg/mL) in the culture media at 16 hrs of treatment (n = 3, *p < 0.05, **p < 0.01, ***p < 
0.001).
Preincubation with the TLR4 blocker TAK-242 (1 ng/ml) for an hour 
decreased MCP-1 release by 90% (p<0.001) compared to Fetuin A with 
palmitic acid. Similarly, the anti-IL-1β antibody reduced MCP-1 secretion by
53.4  17% (p<0.001) and the IL-1Ra (anakinra) by 30  8.8% (p<0.001) 
(Figure 9).
3.1.5. IL-1Ra and anti-IL-1β antibody attenuate Fetuin-A 
exacerbated palmitic acid induced podocyte death
To examine whether the injurious effect of FetA involves IL-1 signaling, 
podocytes were preincubated with anti-IL-1β or IL-1Ra for one hour before 
incubation with palmitic acid or palmitic acid and FetA for 48 hours. Both, 
the anti-Il-1β antibody and recombinant IL-1Ra significantly reduced 
apoptosis by 33.6  6.2% (p<0.05), 30.2  6.2% (p<0.05), and necrosis by 
28.7  4.7% (p < 0.05) and 31.9  3.4% (p<0.01), respectively (Figure 10).
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Figure 10: Bovine Fetuin-A exacerbates palmitic acid induced podocyte death, and TLR4 
blockage or neutralizing IL-1ß is protective. Podocytes preincubated for 1 h with 3.3 
μg/mL anti-IL-1β antibody or 1 μg/ml anakinra were treated with 200 μM palmitic acid 
alone or in combination with 200 μg/ml FetA for 48 hrs. Bar graph represents mean 
percentages ± SD of apoptotic and necrotic cells. (n = 3, ** p < 0.01).
3.1.6. Antagonizing IL-1 protects from palmitic acid induced 
podocyte death, and from podocyte death induced by the 
combination of LPS and palmitic acid
Similarly to the results shown in figure 10, IL-1Ra reduced the combined 
toxic effect of palmitic acid and LPS by a reduction in apoptosis of 44.5 ± 
14.2% (p < 0.01) and necrosis of 23 ± 12.6% (NS) (Figure 11). 
Interestingly, IL-1Ra was also able to reduce palmitic acid induced 
apoptosis and necrosis (Figure 11) and for the anti-IL-1β antibody I could 
observed a reduction of palmitic acid induced apoptosis by 47 ± 10.5% (p 
< 0.01) (Figure 12).
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Figure 11: IL-1R antagonist protects from palmitic acid induced podocyte death, and 
from podocyte death induced by the combination of LPS and palmitic acid. Podocytes 
preincubated for 1 h with 1 μg/mL anakinra were treated with 200 μM palmitic acid alone or in 
combination 1 ng/ml LPS for 48h. Bar graph represent mean percentages ± SD of apoptotic and 
necrotic cells. (n = 3, * < 0.05, ** p < 0.01).
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Figure 12: Anti IL-1ß Ab ameliorates podocyte death induced by palmitic acid. Podocytes 
preincubated for 1h with 3.3 μg/mL anti-IL-1β antibody and exposed to 200 µM palmitic acid for 48 
hrs. Bar graph represents mean percentages ± SD of apoptosis and necrosis (n = 3, **p < 0.01).
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3.1.7. Interleukin-1β in combination with palmitic acid 
exacerbates podocyte death
In the next step, podocytes were treated with either 200 μM palmitic acid 
or BSA (control) in the presence or absence of 5 ng/ml IL-1β for 48 hrs. The
treatment with palmitic acid combined with IL-1β significantly accentuated
the toxicity caused by palmitic acid, i.e. increases of necrosis and 
apoptosis by 190  24% (p < 0.001) and 217  35% (p < 0.001) were 
observed (Figure 13). The effect of IL-1β alone on podocyte death was 
minimal and did not reach statistical significance.
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Figure13: IL-1ß aggravates podocyte death induced by palmitic acid. Podocytes were 
exposed to 200 µM palmitic acid in the presence or absence of 5 ng/ml IL-1β for 48 hrs. Bar graph 
represents mean percentages ± SD of apoptosis and necrosis (n = 3, ***p < 0.001).
3.2. Pilot experiment with anti-IL-1β antibody in diabetic 
mice
3.2.1. Anti IL-1β treatment reduces serum Fetuin-A levels in 
diabetic mice
To complement our in vitro findings we investigated the effect of the anti-
IL-1β antibody in diabetic DBA/2J (DBA) mice.
Table 2 shows the characteristics of DBA/2J mice injected with STZ along 
with mouse IL-1β antibody or saline control. As indicated in table 2, 
average fasting blood glucose levels were 3 fold higher in diabetic mice 
than in control mice at the end of the experiment.
Table 2: Metabolic characteristics of DBA/2J mice experiment:
Control + 
Saline
Control + 
anti IL-1β 
Ab
STZ (HFD)+ 
saline
STZ (HFD)+ 
anti IL-1β Ab
Age (weeks) at start 
of experiment
9 9 9 9
Weight at induction 
of Diabetes (g)
26.5 ± 
0.96
26.5 ± 1.82 25.8 ± 1.53 25.7 ± 1.35
Weight at end of 
experiment (g)
33.3 ± 
2.35
33.3 ± 2.85 24.8 ± 2.06 25.5 ± 1.67
Fasting Blood 
Glucose (mmol/l) at 
10 day after STZ 
injection
5.5 ± 0.88 5.6 ± 0.27 11.2 ± 2.55 12.0 ± 2.48
Fasting glucose 
(mmol/l) at the end 
of experiment
5.8 ± 1.72 5.4 ± 0.86 17.4 ± 2.06 18.0 ± 2.04
Data are means ± SD (n = 6 mice in each group)
As shown in figure 14, serum FetA levels were significantly upregulated in 
diabetic mice (188 ± 16.4%, p < 0.001) compared to control mice. The 
administration of the anti IL-1β antibody reduced the FetA levels by 63.3 ±
5% (p < 0.001).
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Figure 14: Anti-IL-1ß treatment reduces serum Fetuin-A in DBA/2J diabetic mice. Serum 
FetA was quantified in diabetic mice treated with an anti-IL-1β antibody (or vehicle) for 4 weeks 
(see method for experimental details). Bar graph represents serum FetA (ng/ml) levels ± SD in 
treated and untreated diabetic DBA/2J mice (n = 6, *** p < 0.001).
In another experiment, C57BL6/N were made diabetic by feeding a HFD for
4 weeks followed by an injection with a single dose of STZ at 130mg/kg of 
mouse. Table 3 shows the metabolic parameters of these mice. The fasting
glucose levels were 1.9 fold higher in diabetic mice (HFD + STZ) compared
to the control mice (chow diet + saline).
Table 3: Metabolic characteristics of B6 mice experiment:
Control + 
Saline
Control + 
anti IL-1β 
Ab
HFD/STZ+ 
saline
HFD/STZ+ anti
IL-1β Ab
Age (weeks) at start 
of experiment
9 9 9 9
Weight at induction 
of Diabetes or before 
STZ injection (g)
27.2 ± 
0.93
27.2 ± 1.06 27.2 ± 1.66 27.2 ± 0.93
Weight at end of 
experiment (g)
31.5 ± 
2.08
32.1 ± 2.42 28.2 ± 2.64 28.8 ± 2.07
Fasting glucose 
(mmol/l) at the end 
of experiment
5.5 ± 1.60 6.9 ± 1.26 10.39 ± 6.6 9.31 ± 2.50
Data are presented as arithmetic mean ± SD (n =6 mice in each group)
Treating the B6 with anti-IL-1β Ab significantly reduced serum FetA levels 
in diabetic mice (figure 15) by 21.3 ± 9.3% (p < 0.05).
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Figure 15: Anti-IL-1ß treatment reduces serum Fetuin-A in C57BL6/N diabetic mice. 
Serum FetA was quantified in diabetic mice treated with an anti-IL-1β antibody (or vehicle) for 4 
weeks (see method for experimental details). Bar graph represents serum FetA (ng/ml) levels ± SD 
in treated and untreated diabetic B6 mice (n = 6, * p < 0.05).
3.2.2. Anti IL-1β treatment reduced urinary TNF-α levels in 
diabetic mice
As previous studies demonstrated that there is an increase in urinary TNF-
α levels during the progression of albuminuria (Kalantarinia, Awad, & 
Siragy, 2003), we investigated whether treatment with the anti-IL-1β 
antibody affects urinary TNF-α in the model of diabetic DBA/2J mice. Figure
16 shows that diabetic mice showed increased TNF-α levels in the urine by
69.1 ± 18.5% (p < 0.01) compared to non-diabetic control mice. Treatment
with the anti-IL-1β Ab significantly reduced TNF-α levels by 70.5 ± 2% (p <
0.001) compared to diabetic mice treated with saline.
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Figure 16: Anti-IL-1ß treatment reduces urinary TNF-alpha in diabetic DBA/2J mice. Urine 
TNF-α levels were quantified in diabetic mice treated with an anti-IL-1β antibody (or vehicle) for 4 
weeks (see method for experimental details). Bar graph represents urine TNF-α levels (ng/ml) in 
treated and untreated diabetic DBA/2J mice (n=6; **p< 0.01, ***p<0. 001).

3.2.3. Short term anti-IL-1β treatment has no beneficial effect
on urinary albumin levels in diabetic mice
To investigate if anti-IL-1β treatment affects urinary albumin levels in 
diabetic DBA/2J mice, albuminuria was measured. As shown in figure 17, 
albumin levels were significantly increased from control group to STZ 
group by 299.2 ± 74.2% (p < 0.01). However, there is no significant 
difference in albumin levels between treated group (STZ/HFD + anti-IL-1β 
Ab) and control (STZ/HFD + saline).
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Figure 17: Anti-IL-1ß effect on urine albumin excretion in diabetic DBA/2J mice.
Urine was quantified in diabetic mice treated with an anti-IL-1β antibody (or vehicle) for 4 
weeks (see method for experimental details). After 10 days of injection, STZ groups were 
placed on high fat diet (HFD) and control groups were maintained on chow diet for four 
weeks. Anti IL-1β antibody was administered at 10 µg/g of mice for first two weeks and 
then concentration of antibody was maintained at 5 µg/g of mice. Bar graph represents 
mean (SD) of urinary albumin levels collected for 24 hrs (n=6, ** p<0.01)
4. DISCUSSION
In the present study, we demonstrate that FetA aggravates palmitic acid 
induced podocyte death. This effect is associated with an inflammatory 
response and involves IL-1β.
Several lines of evidence suggest that the deleterious effect of FetA 
involves TLR4 signaling. Specifically, using genetically engineered HEK-
Blue hTLR4 cells as a reporter system FetA led to a dose-dependent signal 
by increasing FetA from 50 to 150 ug/ml. A similar dose response was 
observed with the prototypical TLR4 ligand LPS. In contrast to FetA, the 
dose of LPS was increased logarithmically from 10 up to 104 pg/ml. This 
suggests that the mechanism of FetA on TLR4 may differ from LPS. To 
minimize interference with any residual endotoxin contamination, FetA was
cleaned with polymyxin B and residual endotoxin concentrations were 
below 0.1 EU/ml. As the source of murine FetA tried up during the study 
we were forced to switch to bovine FetA (experiments performed with 
murine FetA are limited to Fig. 5 and 6). For an unexplained reason, the 
results with the HEK-Blue-hTLR4 reporter cell line could not be confirmed 
with bovine FetA (data not shown). A species difference may account for 
this difference. Importantly, in podocytes both bovine and murine FetA 
significantly stimulated MCP-1 release (Fig. 3, 5 and 9) which was further 
increased by the FFAs palmitic or oleic acid. Consistent with the reporter 
assay data, the specific TLR4 inhibitor TAK-242 (Matsunaga, Tsuchimori, 
Matsumoto, & Ii, 2011) prevented the MCP-1 release in podocytes (Fig. 5 
and 9) and our data suggests that the observed proinflammatory response
involves TLR4 signaling.
Interestingly and in contrast to previous studies using other cells including 
pancreatic β-cells (Boni-Schnetzler et al., 2009; Lee, Sohn, Rhee, & Hwang,
2001; Shi et al., 2006), no stimulation of MCP-1 or KC could be observed in 
podocytes incubated with palmitic acid alone although palmitic acid 
together with FetA exacerbated the inflammatory response. This may be 
explained by inherent differences of specific cell types. Alternatively, most 
cell culture studies are performed with 10% fetal bovine serum (FBS), 
which contains about 20 mg/ml FetA (Pal et al., 2012). Previously it has 
been suggested that FetA, FFAs, and TLR4 build a ternary complex (Pal et 
al., 2012). Alternatively, palmitic acid may augment TLR4 signaling by 
enhancing the concentration of the sphingolipid ceramide (Jin et al., 2013) 
which is known to affect cell signaling at multiple levels, e.g. by 
modulation of raft composition and assembly of the TLR4 signaling 
complex (Plociennikowska, Hromada-Judycka, Borzecka, & Kwiatkowska, 
2015). As FetA is well known as a carrier protein (Cayatte et al., 1990) an 
intriguing hypothesis is that it acts as a sink for FFAs and endotoxin 
thereby potentially increasing their local concentration or availability. 
Clearly, more experiments are needed to clarify the exact interplay 
between FetA, FFAs, and TLR4.
Of note, both FetA and LPS had no effect on podocyte survival but 
exacerbated palmitic acid induced podocyte death and this could be 
partially prevented by the TLR4 inhibitor TAK-242 (Fig. 5 and 6). The 
finding that LPS exacerbated palmitic acid induced podocyte death may at
least in part explain albuminuria in septic patients (Basu et al., 2010) as 
bacterial endotoxins and FFAs are increased in this setting (Nogueira et al.,
2008).
Remarkably and unexpectedly, TAK-242 dramatically reduced palmitic acid
induced podocyte death. As FetA, BSA, and palmitic acid complexed to 
BSA were cleaned with polymyxin B, stimulation of TLR4 by any residual 
endotoxin concentration is unlikely, but cannot be excluded. If so, such a 
residual endotoxin concentration would be in the lower range of healthy 
human blood donors, reported to be between 1.00 – 0.01 EU/ml (Nadhazi, 
Takats, Offenmuller, & Bertok, 2002). Alternatively, the protective effect of 
TAK-242 on palmitic acid induced podocyte death could be explained by a 
constitutively active TLR4 in podocytes. Although TAK-242 binds 
specifically to an intracellular domain of TLR4 (Matsunaga et al., 2011) we 
cannot rule out a protective off-target effect. Excluding the later 
possibility, our data are entirely consistent with and extend previous 
reports indicating that TLR4 signaling can adversely affect the kidney and 
contributes to DN (J. Wada & Makino, 2016).
An interesting outcome of the current study was that inhibition of IL-1 
signaling by anakinra, a recombinant human IL-1Ra, or a murinized anti-IL-
1β antibody could attenuate the inflammatory response elicited by FetA 
and palmitic acid. Similarly, anakinra and the anti-IL-1β antibody 
attenuated podocyte death induced by combined treatment with palmitic 
acid and FetA or by palmitic acid alone. This clearly indicates that palmitic 
acid induced podocyte death is partially mediated by IL-1β. Interestingly, 
podocyte death could not be induced by IL-1β alone as it was previously 
reported in pancreatic beta-cells (Maedler et al., 2004), however IL-1β was 
able to exacerbate palmitic acid induced podocyte death. Together this 
indicates that the proapoptotic effect of IL-1β depends on a second hit 
elicited by palmitic acid or by the combination of palmitic acid and FetA in 
podocytes.
In a pilot study we investigated the effect of a murinized anti-IL-1β 
antibody in insulinopenic DBA/2J mice (STZ model) put on a high fat diet. 
Although the experiment had to be terminated prematurely after five 
weeks and no beneficial effect on the threefold increase in albuminuria 
could be observed, treatment with the anti-IL-1β antibody largely 
prevented the substantial increase in the serum FetA concentration. This 
observation could be confirmed in a second pilot experiment using a 
slightly different protocol using C57B6/N mice. Together with our in vitro 
data, this observation is tempting to hypothesize that the lower FetA 
concentrations may serve a surrogate marker and may predict longtime 
protection by the anti-IL-1β antibody against DN. In this context, a 
community-based study in China is particularly interesting as people in the
highest FetA tertile had a 2-fold increased risk for developing albuminuria 
over a follow up period of four years (Lv et al., 2016). Moreover, treatment 
with the anti-IL-1β antibody suppressed the increase in urinary TNF-α 
levels observed in diabetic mice. This indicates a protective effect of an 
anti-IL-1β therapy as urinary TNF-α is a risk factor for albuminuria 
(Kalantarinia et al., 2003) and TNF-α is reported to induce podocyte death 
(Ryu, Mulay, Miosge, Gross, & Anders, 2012; Tejada et al., 2008). Using a 
different approach a recent study demonstrated the likely important role of
IL-1 signaling and of the inflammasome in the pathogenesis of DN. In this 
study mice deficient in Nlrp3 (nucleotide-binding domain and leucine-rich 
repeat pyrin 3 domain) in non-myeloid-derived cells were protected from 
DN (Shahzad et al., 2015). Furthermore anakinra protected from or even 
reverse DN in different mouse models (Shahzad et al., 2015). Therefore, 
prolonged treatment with the anti-IL-1β antibody is likely to show a 
protective effect beyond decreasing serum FetA and urinary TNF-α levels 
and further in vivo studies are needed to investigate this therapeutic 
approach for the prevention and treatment of DN.
5. CONCLUSION
The present study emphasizes the critical role of inflammation for the 
survival of podocytes. The results reported indicate that pro-inflammatory 
cytokines and chemokines downstream of TLR4 mediate palmitic acid 
induce podocyte death.
The results suggest that FetA alone or in combination with FFAs stimulate 
pro-inflammatory cytokines and chemokines in podocytes through TLR4 
activation and in this way modulate podocyte survival. More specifically, 
LPS or FetA alone failed to induce podocyte death but consistently 
exacerbated palmitic acid induced podocyte death and inhibition of TLR4 
prevented MCP-1 and KC release in podocytes and reduced podocyte 
death induced by palmitic acid alone or in combination with FetA.
Moreover, the data presented here indicate that IL-1 plays a key role in 
palmitic acid induced podocyte death, as an anti-IL-1 antibody or the 
recombinant IL-1Ra antagonist anakinra attenuated podocyte death 
induced by palmitic acid alone or in combination with FetA.
In vivo, therapy with a murinized anti-IL-1β antibody for 5 weeks in STZ 
treated DBA/2J mice was not able to protect from albuminuria, but 
prevented an increase in serum FetA concentrations and considerably 
decreased TNF expression in urine, calling for prolonged studies to clarify 
this therapeutic approach.
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